Table 3.
Multivariable analysis assessing factors associated with Adverse Events Following Immunization (AEFIs).
| Variable | Multivariable Analysis | |
|---|---|---|
| Beta Coefficients (SE) | p Value | |
| EDSS | −0.08 (0.08) | 0.30 |
| Disease duration | 0.02 (0.01) | 0.10 |
| Age | −0.02 (0.01) | 0.03 |
| Sex (female vs. male) | 0.361 (0.09) | <0.001 |
| DMTs | ||
| No therapy | Ref | Ref |
| Interferon Beta 1-a | 0.263 (0.185) | 0.156 |
| Interferon Beta 1-b | −0.361 (0.367) | 0.326 |
| Glatiramer Acetate | 0.071 (0.228) | 0.756 |
| Teriflunomide | 0.118 (0.213) | 0.579 |
| Dimethyl fumarate | 0.094 (0.193) | 0.626 |
| Natalizumab | 0.068 (0.197) | 0.730 |
| Fingolimod | 0.099 (0.202) | 0.625 |
| Ocrelizumab | 0.477 (0.208) | 0.022 |
| Cladribine | 0.101 (0.236) | 0.669 |
| Other treatment | −0.171 (0.357) | 0.631 |
EDSS: Expanded Disability Status Scale; DMT: Disease Modifying Therapies; SE: Standard Error.